Top news of the week: 24.11.2020.
#biotechnology #biospace #lifesciences #pharmaceuticals #biotech #WhyKBI
Companies And Industries
Biopharma Money on the Move: November 11-17
#biospace #lifesciences #biotechnology #pharmaceuticals
https://t.co/nBHNNrWyPE
OpenBiopharma Money on the Move: November 11-17
Find out which biopharma companies are raking in cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.
Innovative New Biotech Aims to Bring More Effective Immunotherapies to Patients
#biospace #lifesciences #biotechnology #pharmaceuticals #biotech
https://t.co/MMYabugB90
OpenInnovative New Biotech Aims to Bring More Effective Immunotherapies to Patients
Immunotherapies are about to get safer, more effective, and even more accessible with the new biotech’s novel approach.
KBI’s extensive process development and analytical development capabilities help our partners generate active product at an attractive cost while enabling rapid, reliable transfer to cGMP manufacturing. Find out #WhyKBI Analytical Development: https://t.co/1jsSTCKeRh https://t.co/YvTswm2r6l
OpenBiopharmaceutical process development services
KBI’s extensive process development and analytical development capabilities help our partners generate active product at an attractive cost while enabling rapid, reliable transfer …
As COVID-19 vaccine research revs up, so do cyberattacks: report
A new report on the biopharma industry by cybersecurity firm Bluevoyant LLC found that the eight most prominent players in the race for a COVID-19 vaccine faced the highest volume of ...
Stock sales amid vaccine news renew calls for 10b5-1 ‘cooling-off’ period https://t.co/GFgoVr1vgX
OpenStock sales amid vaccine news renew calls for 10b5-1 ‘cooling-off’ period
Concerns about biopharma executives profiting from stock sales aligned with releases of promising COVID-19 vaccine results could result in Congress requiring a cooling-off period for ...
Join us Wednesday, December 16 for this free video webinar "Scientific Collaboration Using Innovative Remote Technologies." Sponsored by @MilliporeSigma. Register today: https://t.co/gCs8C0SEX9 https://t.co/mUNRFUWVRB
OpenRegister for Webinar: Scientific Collaboration Using Innovative Remote Technologies
When COVID-19 started to spread across continents and become a global pandemic, biopharma manufacturers around the world faced two major challenges: (1) enter the race for treatment of the ...
Merck to pay $425M for biotech to get Covid-19 drug, but says manufacturing will be a challenge
Also: Roger Perlmutter on what's next for $MRK's vaccine.
https://t.co/VPhjpWX2Sy
OpenMerck to pay $425M for biotech to get Covid-19 drug, but says manufacturing will be a challenge
The drug giant Merck said it would purchase Rockville, Md.-based OncoImmune in order to obtain the company’s Covid-19 treatment.
Raging at the pandemic, a VC raises $800M for a company that aims to transform biotech manufacturing
The board of the new company, Resilience, includes a who’s who of former industry and government officials.